|
PIGP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.82850000485635E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.70749999994779E-06 |
| Normal-vs-Stage2 |
1.319080E-03 |
| Normal-vs-Stage3 |
6.23010000255775E-08 |
| Normal-vs-Stage4 |
2.15069995146422E-09 |
| Stage1-vs-Stage2 |
6.775000E-01 |
| Stage1-vs-Stage3 |
5.094400E-02 |
| Stage1-vs-Stage4 |
1.201810E-02 |
| Stage2-vs-Stage3 |
1.074580E-01 |
| Stage2-vs-Stage4 |
2.158300E-02 |
| Stage3-vs-Stage4 |
3.849600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.80989997936132E-09 |
| Normal-vs-AfricanAmerican |
2.264400E-03 |
| Normal-vs-Asian |
1.417050E-04 |
| Caucasian-vs-AfricanAmerican |
4.738000E-01 |
| Caucasian-vs-Asian |
1.913180E-01 |
| AfricanAmerican-vs-Asian |
8.245600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.43749999961906E-07 |
| Normal-vs-Female |
1.9804999995543E-07 |
| Male-vs-Female |
5.205000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.99189999999994E-06 |
| Normal-vs-Age(41-60Yrs) |
1.61120000008452E-07 |
| Normal-vs-Age(61-80Yrs) |
7.06420000051722E-07 |
| Normal-vs-Age(81-100Yrs) |
7.72940000000055E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.631800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.994220E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.183500E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.209400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.489970E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.133000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.205570E-01 |
| Classical-VS-Follicular |
2.081500E-03 |
| Classical-VS-Other |
9.067800E-01 |
| Classical-VS-Normal |
7.42520001040248E-09 |
| Tall-VS-Follicular |
3.962300E-03 |
| Tall-VS-Other |
5.126800E-01 |
| Tall-VS-Normal |
2.23949999988982E-07 |
| Follicular-VS-Other |
3.093000E-01 |
| Follicular-VS-Normal |
7.659700E-03 |
| Other-VS-Normal |
9.303500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.79235999999694E-05 |
| Normal-vs-N1 |
4.57840000023246E-07 |
| N0-vs-N1 |
1.273570E-01 |
|
|
